Wednesday 26 June 2024

Immuron (ASX:IMC): Developing & commercialising a novel class of targeted polyclonal antibodies

Immuron (ASX:IMC, NASDAQ:IMRN) is a dual-listed commercial and clinical stage biopharmaceutical company with a proprietary technology platform. Immuron currently has three drug candidates in clinical development. Ahead of appearing at Peak Asset Management’s Sky High Luncheon to discuss Immuron’s investment proposition is Chief Executive Officer Steven Lydeamore, joining The Stock Network’s Lel Smits.

1. Therapeutic drug candidates
Steven, can you start by giving us an overview of Immuron’s therapeutic drug candidates and what conditions are they targeting to treat?

2. Product portfolio
What is the correct status of Immuron’s product portfolio and recent operational developments?

When it comes to driving value for shareholders where would you like to see the company 12 months from now?

Subscribe to TSN’s YouTube channel for the latest stock content:
_ _ _

Follow TSN for the latest stock news and interviews:

_ _ _
Connect with our host Lel Smits online – @LelSmits
– Twitter / X:
– Instagram:
– LinkedIn:
– TikTok:
– Facebook:
– Threads:
_ _ _

The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss.

This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer.

_ _ _

Visit TSN’s website to sign up for regular stock updates:
_ _ _

Free stock updates

Subscribe to receive the latest stock news, CEO interviews, expert insights, events and offers directly into your inbox